Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma

Data Availability

Individual participant data underlying the results reported in this publication, along with a data dictionary, will be made available to approved investigators for secondary analyses following the completion of the objectives of the United States Expanded Access Program to COVID-19 convalescent plasma. Limited and de-identified data sets will be deposited into a research data repository and may be shared with investigators under controlled access procedures as approved by the Mayo Clinic Institutional Review Board. A scientific committee will review requests for the conduct of protocols approved or determined to be exempt by an Institutional Review Board. Requestors will be required to sign a data use agreement. Data sharing must be compliant with all applicable Mayo Clinic policies.